Aquestive Therapeutics (NASDAQ:AQST) · earnings miss
Quarter
Q2
EPS estimate to actual
-$0.12→ to -$0.18
Revenue estimate to actual
$11.7M→ to $13.8M
At a glance
Key takeaways
01Aquestive Therapeutics reported Q2 2026 earnings per share of -$0.18, missing the consensus estimate of -$0.12 by $0.06 per share, representing a 50% miss relative to expectations.
02Revenue of $13.8M beat analyst estimates of $11.7M, indicating stronger-than-expected sales despite the earnings miss.
03The stock trades at $4.41 with a market capitalization of $397.2M, and the earnings miss puts pressure on the stock as investors reassess growth assumptions.
04This quarter's loss per share of -$0.18 represents a deterioration from Q1's -$0.07 loss, suggesting the business is decelerating rather than stabilizing.
Earnings Results
Aquestive Therapeutics (NASDAQ:AQST) reported quarterly earnings results on August 11, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $-0.18, missing the consensus estimate of $-0.12 by $0.06 per share. Revenue came in at $13.8M, beating the estimate of $11.7M.
Company Overview
Aquestive Therapeutics's stock moved following the earnings release. The stock currently trades at $4.41 with a market capitalization of $397.2M.
Missing analyst estimates puts pressure on a stock as investors reassess their growth assumptions. The market's reaction to an earnings miss depends heavily on the magnitude of the shortfall, the company's forward guidance, and whether the miss was driven by temporary or structural factors.
The 50% miss relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Aquestive Therapeutics should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.